中文

Untranslated

English
Chinese
French
German
Portuguese
Spanish
Russian
Japanese
Korean
Arabic
Irish
Greek
Turkish
Italian
Danish
Romanian
Indonesian
Czech
Afrikaans
Swedish
Polish
Basque
Catalan
Esperanto
Hindi
Lao
Albanian
Amharic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Bulgarian
Cebuano
Chichewa
Corsican
Croatian
Dutch
Estonian
Filipino
Finnish
Frisian
Galician
Georgian
Gujarati
Haitian
Hausa
Hawaiian
Hebrew
Hmong
Hungarian
Icelandic
Igbo
Javanese
Kannada
Kazakh
Khmer
Kurdish
Kyrgyz
Latin
Latvian
Lithuanian
Luxembou..
Macedonian
Malagasy
Malay
Malayalam
Maltese
Maori
Marathi
Mongolian
Burmese
Nepali
Norwegian
Pashto
Persian
Punjabi
Serbian
Sesotho
Sinhala
Slovak
Slovenian
Somali
Samoan
Scots Gaelic
Shona
Sindhi
Sundanese
Swahili
Tajik
Tamil
Telugu
Thai
Ukrainian
Urdu
Uzbek
Vietnamese
Welsh
Xhosa
Yiddish
Yoruba
Zulu
Kinyarwanda
Tatar
Oriya
Turkmen
Uyghur

More Language

86-21-64556180

cpd-service@caerulumpharma.com

Gida
Game da Mu
Kayayyaki
Magani
Albarkatu
- Zazzagewa
- Gidan hotuna
FAQs
Tuntube Mu

Gida
Kayayyaki
Kwayoyin bioactive
Antineoplastic
BCl2-BH4

Rukunin samfuran

Antineoplastic
- ACC
- Adenosin A2A
- ALK
- Androgen receptor inhibitor
- Apoptosis stimulant
- ATR
- Farashin AXL
- BCl2-BH4
- Bcr-Abl
- Farashin BRAF
- BTK
- CDK
- Chk1
- CYP17
- DNA alkylating wakili
- EED
- Farashin EGFR
- EP4
- ER
- FAK
- FGFR
- Saukewa: FLT3
- Glutaminase
- IDO
- IRA
- KIT
- LXR
- MDM2
- MEK
- MET
- Nrf2
- Saukewa: P90RSK
- P97
- PAKS
- PARP
- PI3K
- Plk-1
- SMYD2
- SRC
- TOPK
- VEGFR
Magungunan hypoglycemic
Wasu
- 5HT
- AMPK
- Arginase
- CRF-1
- CXCR2
- FLAP
- Farashin FXR
- GABA
- Gi activator
- GR
- JAK
- LABA
- mAChRs
- NF-κB
- NRTI
- PPAR
- RIP1
- Farashin S1PR
- SGC
- SYK
- α2-1
- αIIbβ3
- β2-adrenoceptor
- σ1

BCl2-BH4

CAT #	Sunan samfur	Bayani
Saukewa: CPD102300	S-55746

da

Tuntube Mu

No. 401, hawa na 4, Ginin 6, Titin Quwu 589, Gundumar Minhang, 200241 Shanghai, Sin
86-21-64556180
A cikin China:
sales-cpd@caerulumpharma.com
Na duniya:
cpd-service@caerulumpharma.com

Tambaya

Don tambayoyi game da samfuranmu, da fatan za a bar imel ɗin ku tare da mu kuma za mu tuntuɓi a cikin sa'o'i 24.Tambaya

Sabbin Labarai

AstraZeneca yana karɓar haɓakar tsari don magungunan oncology

AstraZeneca yana karɓar haɓaka tsari don ...

AstraZeneca ta sami haɓaka ninki biyu don fayil ɗin cutar sankara a ranar Talata, bayan hukumomin Amurka da na Turai sun karɓi ƙa'idodin ƙa'idodin magungunanta, matakin farko na samun amincewar waɗannan magunguna. ...

Manyan Abubuwa 7 A cikin Binciken Magunguna A cikin 2018

Manyan Abubuwa 7 A Cikin Binciken Magunguna Na...

Kasancewar kasancewa ƙarƙashin matsin lamba don yin gasa a cikin yanayi mai ƙalubale na tattalin arziki da fasaha, dole ne kamfanonin harhada magunguna da fasahar kere-kere su ci gaba da haɓaka cikin shirye-shiryensu na R&D don ci gaba ...

ARS-1620: Sabuwar mai hanawa don K ...

A cewar wani binciken da aka buga a cikin Cell, masu bincike sun kirkiro wani takamaiman mai hanawa don KRASG12C mai suna ARS-1602 wanda ya haifar da koma baya a cikin mice. "Wannan binciken yana ba da shaida a cikin vivo shaida cewa mutant KRAS na iya zama ...

AstraZeneca yana karɓar haɓaka tsari don ...

AstraZeneca ta sami haɓaka ninki biyu don fayil ɗin cutar sankara a ranar Talata, bayan hukumomin Amurka da na Turai sun karɓi ƙa'idodin ƙa'idodin magungunanta, matakin farko na samun amincewar waɗannan magunguna. ...

Manyan Abubuwa 7 A Cikin Binciken Magunguna Na...

Kasancewar kasancewa ƙarƙashin matsin lamba don yin gasa a cikin yanayi mai ƙalubale na tattalin arziki da fasaha, dole ne kamfanonin harhada magunguna da fasahar kere-kere su ci gaba da haɓaka cikin shirye-shiryensu na R&D don ci gaba ...

FAQs
Zazzagewa
Tuntube Mu

Aika Imel

Lambar QR

x

WhatsApp Online Chat!

TOP

Close

Previous Next

Previous Maximize